Constantin Tamvakopoulos and colleagues recently published a study in the Journal of Medicinal Chemistry

The collaborative work by Investigators from BRFAA, the  Tamvakopoulos team (T Karampelas, E Skavatsou and A  Velentza-Albani) with Professor V Sarli’s Medicinal Chemistry team  from the Aristotle University of Thessaloniki and F Bianchini from  the University of Florence describe the design, synthesis and pharmacological evidence that novel analogues of gemcitabine (GEM),  can be used for the targeted delivery of GEM to integrin  overexpressing cancer cells.  Such strategies are important for the treatment of solid tumors since they can increase tumor delivery of  GEM, minimize common side effects associated with treatment and  increase the stability of the therapeutic.

pubmed

Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine
Chatzisideri T, Leonidis G, Karampelas T, Skavatsou E, Velentza-Almpani A, Bianchini F, Tamvakopoulos C *, Sarli V *. J Med Chem. 2021 Dec 30. doi: 10.1021/acs.jmedchem.1c01468. Online ahead of print. PMID: 34967607